EU/3/05/310

Table of contents

About

On 26 August 2005, orphan designation (EU/3/05/310) was granted by the European Commission to United Therapeutics Europe Ltd., United Kingdom, for treprostinil diethanolamine (oral use) for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

The sponsorship was transferred to Unither Therapeutik GmbH, Germany, in February 2019.

Key facts

Active substance
Treprostinil diethanolamine (oral use)
Disease / condition
Treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension
Date of first decision
26/08/2005
Outcome
Positive
EU designation number
EU/3/05/310

Sponsor's contact details

Unither Therapeutik GmbH
Dreieichstrasse 11
64546 Moerfelden-Walldorf
Germany
Tel. +49 6105 27137

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating